Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Vitamin K3H2. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NSD2 | O96028 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | GALK1 | P51570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vitamin K3H2 SCHEMBL5075246 | 1.00 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL297164 | 0.90 | HTT (1.00) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL29525544 | 0.90 | HTT (1.00) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL2887680 | 0.88 | HTT (0.95) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL516200 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL515182 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL28664356 | 0.85 | HTT (0.81) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL28687103 | 0.84 | HTT (0.68) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL515298 | 0.84 | HTT (0.68) | HTTLMNAMAPTKDM4EKMT2A | |
| Vitamin K3H2 SCHEMBL21437091 | 0.84 | HTT (0.72) | HTTLMNAMAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150283290-A1 | STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES | ADHEZION BIOMEDICAL, LLC (US) | 2015-10-08 | — | — | US | claimed |
| JP-2010540159-A | — | — | 2010-12-24 | — | — | JP | claimed |
| JP-2010509991-A | — | — | 2010-04-02 | — | — | JP | claimed |
| EP-2086602-A2 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | Lutonix, Inc. (US) | 2009-08-12 | — | — | EP | claimed |
| EP-2073860-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | Lutonix, Inc. (US) | 2009-07-01 | — | — | EP | claimed |
| EP-2066321-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | Lutonix, Inc. (US) | 2009-06-10 | — | — | EP | claimed |
| WO-2009051614-A1 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20080255508-A1 | Such as balloon and stents; medical device with overcoating of drug with additive; bioavailability | LUTONIX, INC. | 2008-10-16 | — | — | US | claimed |
| US-20080175887-A1 | drug delivering by oral, nasal or pulmonary administration, of rapamycin or paclitaxel drug; additive enhances absorption of drug into body tissue; PEG-fatty acids esters, PEG-fatty alcohol ethers, polyethylene glycol sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene block copolymers | LUTONIX, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008063581-A2 | TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS | LUTONIX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008063576-A2 | DRUG RELEASING COATINGS FOR MEDICAL DEVICES | LUTONIX, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| US-20080118544-A1 | Such as a balloon catheter or a stent; a drug not enclosed in micelles or encapsulated in particles or controlled release carriers and an additive having hydrophobic and hydrophilic portions; improved pharmacokinetics and bioavailability | LUTONIX, INC. | 2008-05-22 | — | — | US | claimed |
| JP-2221201-A | — | — | None | — | — | JP | disclosed |
| JP-62190101-A | — | — | None | — | — | JP | disclosed |
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | ORPHAI THERAPEUTICS INC. (US) | 2026-04-28 | — | — | US | disclosed |
| JP-H02221201-A | SEED-TREATING AGENT AND TREATING METHOD OF SEED | TOMOE KAGAKU KOGYO KK | 1990-09-04 | — | — | JP | disclosed |
| US-4764201-A | Plant growth regulation | TOMOE KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-08-16 | — | — | US | disclosed |
| JP-S62190101-A | MATURITY PROMOTER FOR AGRICULTURAL AND HORTICULTURAL CROP | TOMOE KAGAKU KOGYO KK | 1987-08-20 | — | — | JP | disclosed |
| US-4482492-A | Preparation of vitamins K3 and K4 and derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611398-B2 | Inhalable rapamycin formulation for the treatment of pulmonary hypertension | RICTOR, MTOR, RPTOR | HTT 800/4885LMNA 1497/4885MAPT 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.